Bradykinesia Market to Reach $5.64 Billion by 2029, Growing at a CAGR of 13.4%

Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20

What Market Value Is The Bradykinesia Industry Expected To Reach By 2029, Starting From 2025 Levels?

The market for bradykinesia has demonstrated substantial growth in its size during recent times. Forecasts indicate it will expand from $3 billion in 2024 to $3.41 billion by 2025, achieving a compound annual growth rate (CAGR) of 13.6%. Historically, this expansion can be ascribed to an increasing number of movement disorder clinics, the escalating burden of post-stroke motor complications, the widespread occurrence of hereditary neurodegenerative disorders, a rise in clinical trials for bradykinesia-related therapies, and the continuous development of healthcare infrastructure.

The bradykinesia market size is projected to undergo significant expansion in the next few years. It is expected to grow to $5.64 billion in 2029, achieving a compound annual growth rate (CAGR) of 13.4%. This growth during the forecast period is primarily driven by factors such as the increasing global prevalence of Parkinson’s disease, a rising incidence of various neurological disorders, an aging demographic more prone to neurodegenerative conditions, greater awareness leading to earlier diagnosis of bradykinesia, and the enhancement of diagnostic capabilities within emerging economies. Major trends foreseen in the forecast period include advancements in neurostimulation devices, the development of novel methods for drug delivery, the utilization of wearable technology for tracking motion and monitoring symptoms, an increase in telehealth and remote neurology consultations, and the ongoing development of gene therapy specifically targeting motor dysfunction.

Unlock Your Free Sample Report for Exclusive Market Data:

https://www.thebusinessresearchcompany.com/sample.aspx?id=24487&type=smp

Which Industry Drivers Are Expected To Accelerate The Bradykinesia Market From 2025 To 2029?

The growing occurrence of neurological conditions is expected to drive expansion in the bradykinesia market in the foreseeable future. These disorders are medical states impacting the brain, spinal cord, or nerves, resulting in impaired movement, sensation, cognitive abilities, or various bodily processes. The rise in neurological disorders is linked to the aging global population, given that age-associated alterations in the brain heighten the likelihood of nervous system ailments. The expanding incidence of neurological ailments is boosting the need for bradykinesia treatment, primarily because many of these conditions manifest as slow or diminished movement, thereby increasing the requirement for therapies designed to enhance motor function. As an illustration, in January 2023, the American Parkinson Disease Association (APDA), a US-based advocacy organization, reported that Parkinson’s disease is projected to affect 1.3 million individuals by 2030, signifying a consistent increase in diagnosed cases. Consequently, the rising occurrence of neurological conditions will stimulate the growth of the bradykinesia market.

What Are The Major Segment Categories Driving The Bradykinesia Market Growth?

The bradykinesia market covered in this report is segmented –

1) By Combination Therapy: Mono-Therapy, Combination Therapy

2) By Disease Severity: Early-Stage Parkinson’s, Advanced-Stage Parkinson’s

3) By Symptom Management: Bradykinesia, Tremors, Rigidity

Subsegments:

1) By Mono-Therapy: Levodopa, Dopamine Agonists, MAO-B Inhibitors, Anticholinergics, Amantadine

2) By Combination Therapy: Levodopa And Carbidopa, Levodopa And COMT Inhibitors, Dopamine Agonists And MAO-B Inhibitors, Levodopa And MAO-B Inhibitors, Triple Therapy

What Trends Are Expected To Drive The Bradykinesia Market?

Leading companies within the bradykinesia market are concentrating on creating novel solutions, such as sublingual therapies, to facilitate easier administration, particularly for individuals who struggle with swallowing tablets. Sublingual therapies involve placing medication beneath the tongue, where it is rapidly absorbed into the bloodstream through the mucous membranes for quick effects. For instance, in March 2023, BIAL, a Portugal-based provider of Parkinson’s disease therapeutics, launched KYNMOBI (apomorphine hydrochloride) for the on-demand treatment of OFF episodes in Parkinson’s disease. OFF episodes in Parkinson’s disease are characterized by the reappearance or intensification of symptoms such as bradykinesia, tremor, and rigidity when standard medications lose their effectiveness. The sublingual film formulation of apomorphine hydrochloride presents a fast-acting, on-demand option that dissolves under the tongue. As a non-ergoline dopamine agonist, it aids in managing sudden motor symptom fluctuations. This treatment is typically well-tolerated and supports more consistent symptom control during OFF periods.

Which Leading Players Are Enhancing Their Bradykinesia Market Presence Worldwide?

Major companies operating in the bradykinesia market are AbbVie Inc., Novartis AG, Medtronic Plc, Eli Lilly and Company, Otsuka Pharmaceutical Co. Ltd., Biogen Inc., Eisai Co. Ltd., Kyowa Kirin Co. Ltd., Lundbeck AS, Amneal Pharmaceuticals Inc., Orion Corporation, Acadia Pharmaceuticals Inc., Acorda Therapeutics Inc., Denali Therapeutics Inc., Adamas Pharmaceuticals, Impel NeuroPharma, Annovis Bio Inc., BlueRock Therapeutics LLC, NeuroDerm Ltd., Cerevance LLC, Sage Therapeutics, Anavex Life Sciences Corp., Inhibikase Therapeutics Inc.

Download The Full Report For Exclusive Market Findings:

https://www.thebusinessresearchcompany.com/report/bradykinesia-global-market-report

Which Global Regions Are Influencing The Competitive Landscape Of The Bradykinesia Market?

North America was the largest region in the bradykinesia market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the bradykinesia market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Version Of The Bradykinesia Market Report:

https://www.thebusinessresearchcompany.com/customise?id=24487&type=smp

Browse Through More Reports Similar to the Global Bradykinesia Market 2025, By The Business Research Company

Environment Controllers Market For Agricultural Greenhouse Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/environment-controllers-market-for-agricultural-greenhouse-global-market-report

Biosimilar Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/biosimilar-global-market-report

Market Research Services Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/market-research-services-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795